Advertisement

Topics

AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy

15:00 EDT 10 Aug 2017 | Healio

Applied Genetic Technologies Corporation has filed an investigational new drug application with the FDA to begin a phase 1/2 clinical trial of its gene therapy candidate for X-linked retinitis pigmentosa, according to a company press release.X-linked retinitis pigmentosa, caused by mutations in the RPGR gene, is an inherited condition that causes progressive vision loss. In preclinical data, AGTC’s investigational gene therapy has slowed the loss of visual function in canines with X-linked retinitis pigmentosa, according to the release.

Original Article: AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy

NEXT ARTICLE

More From BioPortfolio on "AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...